Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2027

  • ID: 4330872
  • Drug Pipelines
  • Region: Global
  • 154 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
The ‘Cutaneous T-cell lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CTCL in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous T-cell lymphoma (CTCL) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Cutaneous T-cell lymphoma (CTCL) - Disease Understanding and Treatment Algorithm


The Cutaneous T-cell lymphoma (CTCL) market report gives the thorough understanding of the Cutaneous T-cell lymphoma (CTCL) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous T-cell lymphoma (CTCL) in the US, Europe, and Japan.

Cutaneous T-cell lymphoma (CTCL) Epidemiology

The Cutaneous T-cell lymphoma (CTCL) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by sub-type [Mycosis Fungoides and Others (Sezary syndrome, Primary cutaneous peripheral T-cell lymphoma, unspecified, ATLL, primary cutaneous CD30+ T-cell lymphoproliferative disorders and subcutaneous panniculitis-like T-cell lymphoma (SPTCL)], gender-specific and stage-specific [early stage (IA, IB and IIA) and late stage (IIA, III, IVA and IVB)]

According to the report, the incident cases of CTCL in 7 major markets was 8,310 in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM United States account for highest incident population of CTCL i.e., 3,207 followed by United Kingdom.

Cutaneous T-cell lymphoma (CTCL) Drug Chapters

This segment of the Cutaneous T-cell lymphoma (CTCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently there are six marketed drugs available for the treatment of CTCL including Istodax (Romidepsin), Poteligeo (Mogamulizumab), Valchlor (Mechlorethamine), Uvadex (Methoxsalen), Targretin (Bexarotene) and Zolinza (Vorinostat). Detailed chapters for all of these drugs, along with the promising upcoming therapies including SGX301 (Soligenix Inc), Adcetris (Brentuximab Vedotin), Resminostat (4SC AG) etc have been covered in the report.

Cutaneous T-cell lymphoma (CTCL) Market Outlook

The Cutaneous T-cell lymphoma (CTCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the report, the 7MM market of Cutaneous T-cell lymphoma (CTCL) was USD 353.5 million in 2016, and is expected to increase at a significant growth during the study period i.e., 2016-2027.

Cutaneous T-cell lymphoma (CTCL) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cutaneous T-cell lymphoma (CTCL) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Cutaneous T-cell lymphoma (CTCL) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Cutaneous T-cell lymphoma (CTCL) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous T-cell lymphoma (CTCL) market
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-cell lymphoma (CTCL) market
  • To understand the future market competition in the Cutaneous T-cell lymphoma (CTCL) market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Cutaneous T- Cell Lymphoma Market Overview at a Glance
2.1. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2017
2.2. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2027

3. Cutaneous T- Cell Lymphoma Overview
3.1. Introduction
3.2. Types
3.3. Causes
3.4. Pathophysiology
3.5. Symptoms
3.6. Diagnosis

4. Epidemiology of Cutaneous T-Cell Lymphoma
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. Incident Population of Cutaneous T-Cell Lymphoma
4.1.3. Treatable Cases of Cutaneous T-Cell Lymphoma in the United States
4.1.4. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the United States
4.1.5. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the United States
4.1.6. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the United States
4.1.7. Early Stage Specific Incidence of CTCL in the United States
4.1.8. Late Stage Specific Incidence of CTCL in the United States
4.2. Europe
4.3. Assumptions and Rationale
4.3.1. Germany
4.3.1.1. Incident Population of Cutaneous T-Cell Lymphoma in Germany
4.3.1.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Germany
4.3.1.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
4.3.1.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
4.3.1.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
4.3.1.6. Early Stage Specific Incidence of CTCL in the Germany
4.3.1.7. Late Stage Specific Incidence of CTCL in the Germany
4.3.2. France
4.3.2.1. Incident Population of Cutaneous T-Cell Lymphoma in France
4.3.2.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the France
4.3.2.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France
4.3.2.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France
4.3.2.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France
4.3.2.6. Early Stage Specific Incidence of CTCL in the France
4.3.2.7. Late Stage Specific Incidence of CTCL in the France
4.3.3. Italy
4.3.3.1. Incident Population of Cutaneous T-Cell Lymphoma in Italy
4.3.3.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Italy
4.3.3.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
4.3.3.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
4.3.3.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
4.3.3.6. Early Stage Specific Incidence of CTCL in the Italy
4.3.3.7. Late Stage Specific Incidence of CTCL in the Italy
4.3.4. Spain
4.3.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Spain
4.3.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Spain
4.3.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
4.3.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
4.3.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
4.3.4.6. Early Stage Specific Incidence of CTCL in the Spain
4.3.4.7. Late Stage Specific Incidence of CTCL in the Spain
4.3.5. United Kingdom
4.3.5.1. Incident Population of Cutaneous T-Cell Lymphoma in UK
4.3.5.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the United Kingdom
4.3.5.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
4.3.5.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
4.3.5.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK
4.3.5.6. Early Stage Specific Incidence of CTCL in the UK
4.3.5.7. Late Stage Specific Incidence of CTCL in the UK
4.4. Japan
4.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Japan
4.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Japan
4.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
4.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
4.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
4.4.6. Early Stage Specific Incidence of CTCL in the Japan
4.4.7. Late Stage Specific Incidence of CTCL in the Japan

5. Treatment Algorithm
5.1. International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
5.2. United States
5.3. NCCN Guidelines
5.4. Europe
5.5. ESMO Guidelines
5.6. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
5.7. EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome

6. Unmet Needs

7. Marketed Drugs
7.1. Istodax (Romidepsin): Celgene Corporation
7.1.1. Drug Description
7.1.2. Mechanism of Action
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy
7.1.5. Product Profile
7.2. Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
7.2.1. Drug Description
7.2.2. Mechanism of Action
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Valchlor/ Ledaga (Mechlorethamine): Actelion
7.3.1. Drug Description
7.3.2. Mechanism of Action
7.3.3. Advantages & Disadvantages
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals
7.4.1. Drug Description
7.4.2. Mechanism of Action
7.4.3. Advantages & Disadvantages
7.4.4. Safety and Efficacy
7.4.5. Product Profile
7.5. Targretin (Bexarotene): Eisai Co., Ltd.
7.5.1. Drug Description
7.5.2. Mechanism of Action
7.5.3. Advantages & Disadvantages
7.5.4. Safety and Efficacy of Targretin
7.5.5. Product Profile
7.6. Zolinza (Vorinostat): Merck Sharp & Dohme Corp.
7.6.1. Drug Description
7.6.2. Mechanism of Action
7.6.3. Advantages & Disadvantages
7.6.4. Safety and Efficacy of Zolinza
7.6.5. Product Profile

8. Emerging Drugs
8.1. Phase-III Drugs Analysis – Monoclonal Antibodies and Photodynamic Therapy
8.2. Phase-II Drugs Analysis - Histone Deacetylase (HDAC) Inhibitors

9. Emerging Therapies
9.1. Brentuximab Vedotin: Seattle Genetics
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.1.4. Product Profile
9.2. SGX301: Soligenix
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
9.2.4. Product Profile
9.3. Quisinostat: Janssen
9.3.1. Product Description
9.3.2. Research and Development
9.3.3. Product Development Activities
9.3.4. Product Profile
9.4. Resminostat: 4SC AG
9.4.1. Product Description
9.4.2. Research and Development
9.4.3. Product Development Activities
9.4.4. Product Profile
9.5. Remetinostat: Medivir AB
9.5.1. Product Description
9.5.2. Research and Development
9.5.3. Product Development Activities
9.5.4. Product Profile

10. Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis
10.1. Total Market Size of Early Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027
10.2. Total Market Size of Late Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027
10.3. Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027
10.4. Assumptions and Caveats (7MM)
10.5. United States
10.5.1. Market Outlook
10.5.2. Stage Specific Market Size of CTCL in United States
10.5.3. Market Size of CTCL in United States
10.6. Europe
10.6.1. Market Outlook
10.6.2. Germany
10.6.2.1. Stage Specific Market Size of CTCL in Germany
10.6.2.2. Market Size of CTCL in Germany
10.6.3. France
10.6.3.1. Stage Specific Market Size of CTCL in France
10.6.3.2. Market Size of CTCL in France
10.6.4. Italy
10.6.4.1. Stage Specific Market Size of CTCL in Italy
10.6.4.2. Market Size of CTCL in Italy
10.6.5. Spain
10.6.5.1. Stage Specific Market Size of CTCL in Spain
10.6.5.2. Market Size of CTCL in Spain
10.6.6. United Kingdom
10.6.6.1. Stage Specific Market Size of CTCL in United Kingdom
10.6.6.2. Market Size of CTCL in United Kingdom
10.7. Japan
10.7.1. Market Outlook
10.7.2. Stage Specific Market Size of CTCL in Japan
10.7.3. Market Size of CTCL in Japan

11. Market Drivers

12. Market Restraints

13. Appendix

14. Report Methodology
14.1. Sources Used

15. Publisher Capabilities

16. Disclaimer

17. About the Publisher

List of Tables:
Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027)
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027)
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027)
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027)
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027)
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027)
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027)
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027)
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Table 43: Recommendations for treatment of CTCL by Radiation Therapy
Table 44: Recommendations for treatment of MF stages IA, IB, and IIA
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027)
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027)
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027)
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027)
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 61: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)

List of Figures:
Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027)
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027)
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027)
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027)
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027)
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027)
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027)
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027)
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027)
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027)
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027)
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027)
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027)
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders
Figure 51:Treatment for Lymphomatoid papulosis
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll